Background: Juvenile-onset systemic lupus erythematosus (JSLE) is more severe than adultonset disease, including more lupus nephritis (LN). Despite differences in phenotype/pathogenesis, treatment is based upon adult trials. This study aimed to compare treatment response, damage accrual, time to inactive LN and subsequent flare, in JSLE LN patients treated with mycophenolate mofetil (MMF) versus intravenous cyclophosphamide (IVCYC). Methods: UK JSLE Cohort Study participants, 16 years at diagnosis, with 4 American College of Rheumatology criteria for SLE, with class III or IV LN, were eligible. Mann-Whitney U tests, Fisher's exact test and Chi-squared tests were utilized for statistical analysis. Results: Of the patients, 34/51 (67%) received MMF, and 17/51 (33%) received IVCYC. No significant differences were identified at 4-8 and 10-14 months post-renal biopsy and last follow-up, in terms of renal British Isles Lupus Assessment Grade scores, urine albumin/creatinine ratio, serum creatinine, ESR, anti-dsDNA antibody, C3 levels and patient/physician global scores. Standardized Damage Index scores did not differ between groups at 13 months or at last follow-up. Inactive LN was attained 262 (141-390) days after MMF treatment, and 151 (117-305) days following IVCYC (p ¼ 0.17). Time to renal flare was 451 (157-1266) days for MMF, and 343 (198-635) days for IVCYC (p ¼ 0.47). Conclusion: This is the largest study to date investigating induction treatments for proliferative LN in children, demonstrating comparability of MMF and IVCYC. Lupus (2019) 28, 613-620.
Introduction
Juvenile-onset systemic lupus erythematosus (JSLE), also known as childhood-onset systemic lupus erythematosus (SLE), comprises approximately 15-20% of all SLE cases. Significant differences exist between JSLE and adult-onset SLE (aSLE), with JSLE patients displaying a more aggressive disease course, [1] [2] [3] including more renal involvement. Up to 80% of JSLE patients develop lupus nephritis (LN), 1 compared with only 40-50% of adult SLE patients. 4 ,5 JSLE patients have higher mean SLE disease activity index scores at diagnosis and over their disease course. 2, 4, 5 Furthermore, JSLE patients exhibit greater corticosteroid and immunosuppressive treatment burden over time, 2, 4, 5 with more rapid accrual of disease-related damage as compared to aSLE cohorts. 2, 5, 6 Despite differences in the phenotype and pathogenesis of JSLE versus aSLE, 7 even international recommendations for the treatment of JSLE itself 8 and LN specifically 9 are largely based upon data arising from adult SLE clinical trials. Headto-head comparisons of induction treatments for proliferative, class III/IV International Society of Nephrology/Renal Pathology Society (ISN/RPS) LN in children are lacking. The largest paediatric study available retrospectively compared renal outcomes from seven patients treated with intravenous cyclophosphamide (CYC) (termed IVCYC) and six individuals treated with mycophenolate mofetil (MMF) . 10 This demonstrated a non-statistically significant trend towards more MMF-treated patients achieving LN remission at 6 months. A randomized, openlabel, non-inferiority trial including 140 American adult SLE patients suggested MMF to be more effective than IVCYC. 11 Notably in this study, 56% of patients included were of Black race, and 17% were White. A further study including 370 adult SLE patients did not detect significant differences in renal response rates between IVCYC and MMF induction treatment. 12 A recent meta-analysis of available randomized trials in adults with LN (including 4222 participants across 53 studies) demonstrated MMF, calcineurin inhibitors or their combination to be most effective for inducing LN remission, as compared to IVCYC. 13 The aim of this present study was to use prospectively collected data from the UK JSLE Cohort Study, 1 to compare effectiveness of MMF versus IVCYC induction treatments in patients with juvenile-onset LN, assessing response to treatment, damage accrual, time to achievement of inactive LN and time to subsequent LN flare.
Materials and methods

Patients
Participants of the UK JSLE Cohort Study, 1 monitored between 2006 and 2018, aged 16 years at the time of diagnosis and with 4 American College of Rheumatology SLE classification criteria were included in this study if they had a renal biopsy result demonstrating ISN/RPS class III or IV LN.
14 Patients were excluded if there was inadequate follow-up data to assess response to treatment over the first year. Patients with class III and IV LN were grouped according to whether they received MMF or IVCYC as induction treatment. Concomitant corticosteroid treatment was also documented (oral prednisolone, intravenous methylprednisolone (IVMP) or both). Self-reported ethnicity information was collected in accordance with the UK National Census categorizations. 15 Data of patients who were of mixed race were grouped with those of the associated ethnic minority group. Written patient assent/consent and parental consent was obtained to participate in the UK JSLE Cohort Study, and full ethical approval was in place from the National Research Ethics Service North West, Liverpool East, UK (reference 06/ Q1502/77). The research was carried out in accordance with the Declaration of Helsinki.
Clinical data for assessing response to treatment
At baseline, 4-8 and 10-14 months post-biopsy and the patient's last visit, renal parameters (urine albumin:creatinine ratio, serum creatinine and the renal domain of the British Isles Lupus Assessment Grade (BILAG) score), global disease activity parameters (erythrocyte sedimentation rate (ESR), anti-double-stranded DNA (dsDNA) antibodies, complement factor 3 (C3)) and patient/physician global scores (both 0-100 scale) were collected.
Assessment of LN disease activity and damage
The BILAG score is a composite disease activity measure focusing on nine organs/systems (constitutional, mucocutaneous, neurological, musculoskeletal, cardiovascular/respiratory, renal, gastrointestinal, ophthalmic and haematological). The BILAG score focuses on capturing disease transitions, with the clinician being asked to grade clinical features as new, the same, worse or improving over the last 4 weeks and as compared to the preceding 4 weeks, facilitating accurate assessment of new activity, flare and remission in individual organs/systems. 16 The renal domain of the paediatric BILAG (pBILAG) 2004 disease activity score 1 was used to assess LN disease activity longitudinally. This was calculated from proteinuria, blood pressure, serum creatinine, glomerular filtration rate, active urine sediment and recent renal biopsy findings. The renal pBILAG score is graded from A to E and defined as follows; grade A: severe disease; grade B: moderate disease; grade C: mild/improving disease; grade D: inactive disease but previous system involvement; grade E: system has never been involved. 16 The renal pBILAG score was used to define a change in LN activity, with attainment of inactive LN seen when the renal pBILAG score changed from A, B or C to D; or subsequent flare following initial response to treatment when the renal pBILAG score changed from D to A or B. JSLE-related damage was assessed using the Systemic Lupus International Collaborating Clinics Standardized Damage Index (SLICC-SDI) score 17 at 10-18 months post-renal biopsy.
Statistical analysis
Renal parameters, global disease activity parameters and patient/physician global scores were compared between patients who received MMF or IVCYC as induction treatment. Results are displayed as median values with interquartile ranges or counts and percentages. The data was non-normally distributed (Shapiro-Wilk test), therefore non-parametric tests were employed, using MannWhitney U tests for continuous data and Fisher's exact tests or Chi-squared tests for categorical data. All analysis was undertaken in PRISM version 6.0.
Results
At the time of data analysis (April 2018), the study 
Patient demographics
There were no statistically significant differences between the groups receiving induction therapy with MMF and IVCYC in terms of demographic factors at baseline, including gender, ethnicity, age at diagnosis and age at LN onset (all p > 0.05, see Table 1 ).
Response to treatment and damage accrual
No statistically significant differences were identified between the MMF and IVCYC induction treatment groups at 4-8 and 10-14 months postrenal biopsy and last follow-up, in terms of renal pBILAG score, urine albumin/creatinine ratio, serum creatinine, ESR, anti-dsDNA antibody, C3 levels and patient/physician global scores (all p > 0.05, see Table 2 ). The last follow-up visit occurred after a median of 4.2 years (2.2-7.2) for the MMF treatment group and 3.3 years for the IVCYC group (2.1-5.3). JSLE-related damage did not differ between treatment groups after a median of 13 months (range 10-18 months) post-renal biopsy, with median SLICC-SDI scores of 0 (0-1.0) in the MMF group, and 0 (0-2.5) in the IVCYC group (p ¼ 0.67). Similarly, at the time of the last follow-up, no difference in SLICC-SDI score could be identified (MMF group ¼ 1.0 (0-1.0), IVCYC group ¼ 0 (0-2.5), p ¼ 0.90, see Table 3 ). 
Discussion
The aim of this study was to compare the effectiveness of MMF versus IVCYC as induction treatments in children with LN, using data from the UK JSLE Cohort Study. Within the predominantly Caucasian JSLE study population, MMF and IVCYC were comparably efficacious with regards to treatment response and damage accrual as quantified in this study, and time to next LN flare. Remission was reached slightly sooner with concentration-controlled dose adjustments has been shown to be associated with optimized mycophenolic acid exposure and an excellent renal outcome at 12 months of follow-up in a small sample of adult SLE patients with LN; 18 therefore monitoring of MMF levels could be considered within such a prospective study.
Observations here are complementary to those of Lau et al. 10 who studied a much smaller cohort of American JSLE patients with class III LN (n ¼ 13), and demonstrated a comparable response following MMF or IVCYC induction treatment. The authors reported that at 6 months, no patient had achieved complete remission in the IVCYC group, whilst 57% were in partial remission. In the MMF group, 66% had achieved complete remission, 17% were in partial remission, and 17% were not in remission, leading to the conclusion that MMF may be superior to IVCYC for inducing remission at 6 months, although the small patient numbers precluded any meaningful statistical analysis. The current study differs from reports of Lau et al. in that both class III and IV LN patients were included, and patient numbers allowed for meaningful statistical analyses. Class III and IV LN patients were grouped in the current study on the basis that the recommended treatment for both classes of LN is the same. [19] [20] [21] Further subdivision was precluded by the sample size, especially within the CYC treatment group. These data also support the Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) LN recommendations to use MMF as an induction agent for LN. 9 Results of the current presented study are also in keeping with the reports from Appel et al. in aSLE. 12 Their study is the largest one to date comparing MMF versus IVCYC induction treatment, albeit in adult patients. It comprises a similar group of patients to the current study regarding race (US American; 39% White, 33% Asian, 27% 'other race' versus 47% White, 35% Asian and 18% 'other' in the current UK JSLE Cohort Study). Appel et al. did not detect significant differences in renal response rates between IVCYC and MMF induction treatment. 12 Furthermore, no differences were seen between the MMF and IVCYC groups in relation to adverse events or infections. We are unable to comment on this within the current study, since these data are not collected within the UK JSLE Cohort Study.
Despite being the largest JSLE study to date comparing response to MMF versus IVCYC for LN induction treatment, patient numbers included are relatively small. As per the inclusion criteria for this study, we only considered patients with class III or IV LN rather than all LN patients, for which these treatments are indicated, limiting the number LN patients available for inclusion. The UK JSLE Cohort Study collects patient data alongside routine clinical care. Therefore, reported clinical parameters, patient/physician global scores, SDI data and treatment regimens are recorded over a range of follow-up times post-biopsy, rather than at exact time points. The length of follow-up also varied somewhat between patient groups in the current study, with MMF-treated patients being followed for a median of 4.2 years (2.2-7.2) and IVCYC patients for 3.3 years (2.1-5.3) (although this did not reach statistical significance). Corticosteroid treatment regimens and MMF and CYC dosages may not be identical between centres and treating clinicians, as would be expected within a randomized controlled trial. However, class III and IV LN patients are usually treated with high-dose IVMP pulses (10-30 mg/kg/day, maximum 1000 mg on three consecutive days every 4 weeks) and oral corticosteroids (0.5-2 mg/kg/day, followed by a taper). MMF treatment in the UK usually follows the Euro-Lupus Nephritis Trial protocol 22 and CYC is usually administered at 500-1000 mg/m 2 /day every 4 weeks for a total of 4-6 months. The UK JSLE Cohort Study does not collect sufficient data to compare safety profiles of CYC versus MMF treatments. Rigorous safety data is particularly difficult to collect retrospectively. In light of these limitations, prospective comparison of MMF versus IVCYC induction treatment in larger, ethnically diverse JSLE cohorts, whilst monitoring treatment adherence (e.g. MMF levels), controlling MMF, CYC and corticosteroid dosage (intravenous and oral) and recording drug safety, is warranted to better inform treatment decisions for patients with LN.
Conclusions
This is the largest study to date investigating induction treatments for proliferative LN in JSLE. In predominantly Caucasian JSLE populations, MMF and IVCYC appear to be comparably efficacious in regard to treatment response, damage accrual and time to next flare. Future prospective comparison of MMF versus IVCYC treatment is warranted in ethnically diverse international JSLE cohorts to inform LN treatment protocols, and to explore the relative safety of both treatment regimens.
